{ "disease": "soft-tissue-sarcoma", "label": "Soft tissue sarcoma", "url": "https://usebiotransfer.org/disease/soft-tissue-sarcoma/", "built": "2026-09-12", "facts_hash": { "answers": "d1d19989b54b", "targets": "aa4896f14c6b" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "MDM2", "ensembl": "ENSG00000135679", "n_drug_entries": 4, "n_distinct_drugs": 4, "drugs": { "ALRIZOMADLIN": "PHASE_2", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CDK4", "ensembl": "ENSG00000135446", "n_drug_entries": 17, "n_distinct_drugs": 15, "drugs": { "ABEMACICLIB": "APPROVAL", "AG-24322": "PHASE_1", "ALVOCIDIB": "PHASE_3", "AT-7519": "PHASE_2", "AZD-5438": "PHASE_1", "MILCICLIB": "PHASE_2", "PALBOCICLIB": "APPROVAL", "PHA-793887": "PHASE_1", "RG-547": "PHASE_1", "RGB-286638": "PHASE_1", "RIBOCICLIB": "APPROVAL", "RONICICLIB": "PHASE_2", "TRILACICLIB": "APPROVAL", "UCN-01": "PHASE_2", "VORUCICLIB": "PHASE_1" }, "approved": [ "ABEMACICLIB", "PALBOCICLIB", "RIBOCICLIB", "TRILACICLIB" ], "n_approved": 4, "approved_for": { "ABEMACICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PALBOCICLIB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "RIBOCICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "TRILACICLIB": [ "small cell lung carcinoma", "myelosuppression" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "RB1", "ensembl": "ENSG00000139687", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "PDGFRA", "ensembl": "ENSG00000134853", "n_drug_entries": 33, "n_distinct_drugs": 32, "drugs": { "AMUVATINIB": "PHASE_2", "AVAPRITINIB": "APPROVAL", "BECAPLERMIN": "APPROVAL", "CEDIRANIB": "APPROVAL", "CRENOLANIB": "PHASE_3", "DOVITINIB": "PHASE_3", "ENMD-981693": "PHASE_2", "FAMITINIB": "PHASE_3", "FORETINIB": "PHASE_2", "ILORASERTIB": "PHASE_2", "LINIFANIB": "PHASE_3", "MASITINIB": "APPROVAL", "MIDOSTAURIN": "APPROVAL", "MOTESANIB": "PHASE_3", "NINTEDANIB": "APPROVAL", "NINTEDANIB ESYLATE": "APPROVAL", "OLARATUMAB": "APPROVAL", "ORANTINIB": "PHASE_3", "PAZOPANIB": "APPROVAL", "QUIZARTINIB": "APPROVAL", "REGORAFENIB": "APPROVAL", "RIPRETINIB": "APPROVAL", "SERALUTINIB": "PHASE_3", "SU-014813": "PHASE_2", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "TAK-593": "PHASE_1", "TOVETUMAB": "PHASE_2", "VATALANIB": "PHASE_3", "X-82": "PHASE_2", "XL-820": "PHASE_2", "XL-999": "PHASE_2" }, "approved": [ "AVAPRITINIB", "BECAPLERMIN", "CEDIRANIB", "MASITINIB", "MIDOSTAURIN", "NINTEDANIB", "NINTEDANIB ESYLATE", "OLARATUMAB", "PAZOPANIB", "QUIZARTINIB", "REGORAFENIB", "RIPRETINIB", "SUNITINIB", "SUNITINIB MALATE" ], "n_approved": 14, "approved_for": { "AVAPRITINIB": [ "gastrointestinal stromal tumor" ], "BECAPLERMIN": [ "Skin ulcer" ], "CEDIRANIB": [], "MASITINIB": [], "MIDOSTAURIN": [ "mast cell leukemia", "mastocytosis", "acute myeloid leukemia by FAB classification", "systemic mastocytosis", "acute myeloid leukemia" ], "NINTEDANIB": [ "idiopathic pulmonary fibrosis", "colorectal cancer", "interstitial lung disease", "systemic sclerosis", "pulmonary fibrosis" ], "NINTEDANIB ESYLATE": [ "idiopathic pulmonary fibrosis", "systemic sclerosis", "non-small cell lung carcinoma", "Interstitial pneumonitis" ], "OLARATUMAB": [ "sarcoma", "soft tissue sarcoma" ], "PAZOPANIB": [ "renal cell carcinoma", "soft tissue sarcoma", "sarcoma" ], "QUIZARTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "RIPRETINIB": [ "gastrointestinal stromal tumor" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "NTRK1", "ensembl": "ENSG00000198400", "n_drug_entries": 17, "n_distinct_drugs": 16, "drugs": { "ALTIRATINIB": "PHASE_1", "AZD-6918": "PHASE_1", "AZD-7451": "PHASE_1", "CENEGERMIN": "APPROVAL", "CEP-2563": "PHASE_1", "ENTRECTINIB": "APPROVAL", "GZ-389988": "PHASE_2", "LAROTRECTINIB": "APPROVAL", "LESTAURTINIB": "APPROVAL", "MILCICLIB": "PHASE_2", "PEGCANTRATINIB": "PHASE_2", "PLX-7486": "PHASE_1", "REGORAFENIB": "APPROVAL", "REPOTRECTINIB": "APPROVAL", "SELITRECTINIB": "PHASE_1", "TALETRECTINIB": "PHASE_3" }, "approved": [ "CENEGERMIN", "ENTRECTINIB", "LAROTRECTINIB", "LESTAURTINIB", "REGORAFENIB", "REPOTRECTINIB" ], "n_approved": 6, "approved_for": { "CENEGERMIN": [ "keratitis", "eye disorder" ], "ENTRECTINIB": [ "non-small cell lung carcinoma" ], "LAROTRECTINIB": [ "metastasis" ], "LESTAURTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "REPOTRECTINIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "ALK", "ensembl": "ENSG00000171094", "n_drug_entries": 12, "n_distinct_drugs": 11, "drugs": { "ALECTINIB": "APPROVAL", "ASP-3026": "PHASE_1", "BRIGATINIB": "APPROVAL", "CEP-37440": "PHASE_1", "CERITINIB": "APPROVAL", "CONTELTINIB": "PHASE_1_2", "CRIZOTINIB": "APPROVAL", "ENSARTINIB": "PHASE_3", "ENTRECTINIB": "APPROVAL", "LORLATINIB": "APPROVAL", "PLB1003": "PHASE_1" }, "approved": [ "ALECTINIB", "BRIGATINIB", "CERITINIB", "CRIZOTINIB", "ENTRECTINIB", "LORLATINIB" ], "n_approved": 6, "approved_for": { "ALECTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CERITINIB": [ "non-small cell lung carcinoma" ], "CRIZOTINIB": [ "non-small cell lung carcinoma" ], "ENTRECTINIB": [ "non-small cell lung carcinoma" ], "LORLATINIB": [ "lymphoma", "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Phase 1 Clinical" } ] }, { "symbol": "PDGFRB", "ensembl": "ENSG00000113721", "n_drug_entries": 45, "n_distinct_drugs": 41, "drugs": { "BECAPLERMIN": "APPROVAL", "CATEQUENTINIB": "PHASE_3", "CDP-860": "PHASE_2", "CEDIRANIB": "APPROVAL", "CEP-2563": "PHASE_1", "CM-082": "PHASE_2", "CRENOLANIB": "PHASE_3", "DASATINIB": "APPROVAL", "DOVITINIB": "PHASE_3", "ENMD-981693": "PHASE_2", "FAMITINIB": "PHASE_3", "FORETINIB": "PHASE_2", "ILORASERTIB": "PHASE_2", "IMATINIB": "APPROVAL", "JI-101": "PHASE_2", "LINIFANIB": "PHASE_3", "MASITINIB": "APPROVAL", "MIDOSTAURIN": "APPROVAL", "MOTESANIB": "PHASE_3", "NINTEDANIB": "APPROVAL", "NINTEDANIB ESYLATE": "APPROVAL", "ORANTINIB": "PHASE_3", "PAZOPANIB": "APPROVAL", "QUIZARTINIB": "APPROVAL", "REGORAFENIB": "APPROVAL", "RG-1530": "PHASE_1", "RINUCUMAB": "PHASE_2", "SERALUTINIB": "PHASE_3", "SORAFENIB": "APPROVAL", "SU-014813": "PHASE_2", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "TAK-593": "PHASE_1", "TANDUTINIB": "PHASE_2", "TELATINIB": "PHASE_2", "TG100-801": "PHASE_2", "TIVOZANIB": "APPROVAL", "VATALANIB": "PHASE_3", "X-82": "PHASE_2", "XL-820": "PHASE_2", "XL-999": "PHASE_2" }, "approved": [ "BECAPLERMIN", "CEDIRANIB", "DASATINIB", "IMATINIB", "MASITINIB", "MIDOSTAURIN", "NINTEDANIB", "NINTEDANIB ESYLATE", "PAZOPANIB", "QUIZARTINIB", "REGORAFENIB", "SORAFENIB", "SUNITINIB", "SUNITINIB MALATE", "TIVOZANIB" ], "n_approved": 15, "approved_for": { "BECAPLERMIN": [ "Skin ulcer" ], "CEDIRANIB": [], "DASATINIB": [ "chronic myelogenous leukemia, BCR-ABL1 positive", "acute lymphoblastic leukemia", "blast phase chronic myelogenous leukemia, BCR-ABL1 positive", "lymphoid leukemia" ], "IMATINIB": [ "chronic myelogenous leukemia, BCR-ABL1 positive", "hypereosinophilic syndrome", "myelodysplastic/myeloproliferative disease", "dermatofibrosarcoma protuberans", "gastrointestinal stromal tumor", "blast phase chronic myelogenous leukemia, BCR-ABL1 positive", "B-cell acute lymphoblastic leukemia" ], "MASITINIB": [], "MIDOSTAURIN": [ "mast cell leukemia", "mastocytosis", "acute myeloid leukemia by FAB classification", "systemic mastocytosis", "acute myeloid leukemia" ], "NINTEDANIB": [ "idiopathic pulmonary fibrosis", "colorectal cancer", "interstitial lung disease", "systemic sclerosis", "pulmonary fibrosis" ], "NINTEDANIB ESYLATE": [ "idiopathic pulmonary fibrosis", "systemic sclerosis", "non-small cell lung carcinoma", "Interstitial pneumonitis" ], "PAZOPANIB": [ "soft tissue sarcoma", "renal cell carcinoma", "sarcoma" ], "QUIZARTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "SORAFENIB": [ "renal cell carcinoma", "thyroid gland carcinoma", "hepatocellular carcinoma" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ], "TIVOZANIB": [ "renal cell carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "NF1", "ensembl": "ENSG00000196712", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "SS18", "ensembl": "ENSG00000141380", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "TERT", "ensembl": "ENSG00000164362", "n_drug_entries": 2, "n_distinct_drugs": 1, "drugs": { "IMETELSTAT": "APPROVAL" }, "approved": [ "IMETELSTAT" ], "n_approved": 1, "approved_for": { "IMETELSTAT": [ "anemia", "myelodysplastic syndrome" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CTAG1B", "ensembl": "ENSG00000184033", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "RASDEGAFUSP ALFA": "PHASE_2" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] } ], "trials": { "by_antigen": { "NY-ESO-1": { "n": 48, "n_observational": 1, "n_active": 14, "n_withdrawn": 4, "trials": [ { "nct": "NCT05296564", "title": "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05492682", "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620693", "title": "Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2022-11-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05642455", "title": "SPEARHEAD-3 Pediatric Study", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06083883", "title": "Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644755", "title": "First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06889766", "title": "NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06942143", "title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174427", "title": "Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00027911", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma", "status": "TERMINATED", "last_update": "2013-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00199849", "title": "NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00623831", "title": "A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen", "status": "COMPLETED", "last_update": "2022-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00944580", "title": "A Vaccine Study for High Risk Cancers", "status": "WITHDRAWN", "last_update": "2017-11-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00948961", "title": "A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1", "status": "COMPLETED", "last_update": "2016-06-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01234012", "title": "Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1", "status": "COMPLETED", "last_update": "2015-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01343043", "title": "A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1\u1d9c\u00b2\u2075\u2079T in HLA-A2+ Patients With Synovial Sarcoma", "status": "COMPLETED", "last_update": "2021-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01477021", "title": "Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2014-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "status": "COMPLETED", "last_update": "2016-10-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01883518", "title": "Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2019-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02015416", "title": "A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02059850", "title": "NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma", "status": "WITHDRAWN", "last_update": "2016-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02122861", "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1", "status": "COMPLETED", "last_update": "2019-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02210104", "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells", "status": "WITHDRAWN", "last_update": "2017-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319824", "title": "NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy", "status": "COMPLETED", "last_update": "2017-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02366546", "title": "Investigator Initiated Phase 1 Study of TBI-1301", "status": "UNKNOWN", "last_update": "2018-10-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02387125", "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1", "status": "TERMINATED", "last_update": "2020-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02457650", "title": "T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies", "status": "UNKNOWN", "last_update": "2016-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02609984", "title": "Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)", "status": "TERMINATED", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869217", "title": "Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992743", "title": "Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma", "status": "COMPLETED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03240861", "title": "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2023-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03250325", "title": "Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399448", "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03450122", "title": "Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462316", "title": "NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03520959", "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)", "status": "TERMINATED", "last_update": "2020-04-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03967223", "title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044768", "title": "Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04318964", "title": "TAEST16001 in the Treatment of Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2023-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526509", "title": "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05549921", "title": "Phase II Study of TAEST16001 in Soft Tissue Sarcoma", "status": "TERMINATED", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943990", "title": "Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma", "status": "TERMINATED", "last_update": "2024-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05993299", "title": "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048705", "title": "Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703346", "title": "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma", "status": "COMPLETED", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748872", "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 21, "n_observational": 0, "n_active": 8, "n_withdrawn": 3, "trials": [ { "nct": "NCT05296564", "title": "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620693", "title": "Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2022-11-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06083883", "title": "Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06889766", "title": "NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06942143", "title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01477021", "title": "Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2014-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02059850", "title": "NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma", "status": "WITHDRAWN", "last_update": "2016-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02210104", "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells", "status": "WITHDRAWN", "last_update": "2017-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319824", "title": "NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy", "status": "COMPLETED", "last_update": "2017-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02457650", "title": "T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies", "status": "UNKNOWN", "last_update": "2016-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869217", "title": "Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992743", "title": "Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma", "status": "COMPLETED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03240861", "title": "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2023-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03250325", "title": "Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399448", "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03450122", "title": "Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462316", "title": "NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03967223", "title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526509", "title": "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "NY-ESO-1", "CTAG1B", "afamitresgene", "afami-cel", "Tecelra", "letetresgene" ] }, "MAGE-A4": { "n": 4, "n_observational": 2, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05642455", "title": "SPEARHEAD-3 Pediatric Study", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07613723", "title": "A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03132922", "title": "MAGE-A4\u1d9c\u00b9\u00ba\u00b3\u00b2T for Multi-Tumor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044768", "title": "Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "MAGE-A4", "MAGEA4", "afamitresgene" ] }, "PD-1": { "n": 202, "n_observational": 3, "n_active": 98, "n_withdrawn": 10, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03138161", "title": "SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03465592", "title": "Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03886311", "title": "Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma", "status": "RECRUITING", "last_update": "2025-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282044", "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2024-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04332874", "title": "A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04370587", "title": "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04577014", "title": "Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785196", "title": "APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902443", "title": "Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04995003", "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma", "status": "RECRUITING", "last_update": "2026-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05182164", "title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05264974", "title": "Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05492682", "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05679921", "title": "Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05732831", "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774275", "title": "The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859074", "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05876715", "title": "LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2024-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05961761", "title": "Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients", "status": "RECRUITING", "last_update": "2023-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06066138", "title": "A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074692", "title": "PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)", "status": "RECRUITING", "last_update": "2023-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06113809", "title": "Palbociclib and Pembrolizumab in Sarcoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06114225", "title": "Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial", "status": "RECRUITING", "last_update": "2023-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333314", "title": "Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06345729", "title": "A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-1084-004/KANDLELIT-004)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367075", "title": "A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2025-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06389799", "title": "A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422806", "title": "Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06528769", "title": "Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06683846", "title": "Ivonescimab in the Treatment of Multiple Advanced Tumors", "status": "RECRUITING", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898970", "title": "Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939855", "title": "QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06975293", "title": "STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007273", "title": "Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07089992", "title": "A Study of Pembrolizumab in People With Ultra-Rare Sarcomas", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07139990", "title": "Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153887", "title": "Vebreltinib for Advanced or Metastatic CCS", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223047", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283731", "title": "Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07444619", "title": "A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07602049", "title": "Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07648069", "title": "Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01386502", "title": "CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02122861", "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1", "status": "COMPLETED", "last_update": "2019-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298959", "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02301039", "title": "SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02304458", "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02331251", "title": "Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406781", "title": "Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial", "status": "COMPLETED", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02408861", "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02428192", "title": "Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02432963", "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500797", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "status": "COMPLETED", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636725", "title": "Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2024-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02691026", "title": "A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery", "status": "TERMINATED", "last_update": "2021-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02888665", "title": "Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2021-05-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890368", "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides", "status": "TERMINATED", "last_update": "2023-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02936102", "title": "A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02968303", "title": "Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy", "status": "UNKNOWN", "last_update": "2020-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02982486", "title": "A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma", "status": "UNKNOWN", "last_update": "2017-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03009058", "title": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer", "status": "TERMINATED", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03012620", "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03013127", "title": "A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery", "status": "TERMINATED", "last_update": "2020-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056001", "title": "Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03063632", "title": "Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S\u00e9zary Syndrome and Advanced Synovial Sarcoma", "status": "COMPLETED", "last_update": "2023-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03069378", "title": "A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03092323", "title": "A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03116529", "title": "Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03123276", "title": "Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma", "status": "COMPLETED", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126591", "title": "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03149120", "title": "Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas", "status": "WITHDRAWN", "last_update": "2017-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190174", "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "status": "COMPLETED", "last_update": "2025-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03219671", "title": "Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)", "status": "UNKNOWN", "last_update": "2018-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241745", "title": "A Study of Nivolumab in Selected Uterine Cancer Patients", "status": "COMPLETED", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277924", "title": "Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03282344", "title": "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03307616", "title": "Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03316274", "title": "Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma", "status": "COMPLETED", "last_update": "2024-06-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03316573", "title": "Pembrolizumab in Neoplasms or Lymphomas", "status": "SUSPENDED", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03338959", "title": "Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2024-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03349450", "title": "DPX-Survivac and Checkpoint Inhibitor in DLBCL", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356782", "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03359018", "title": "Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma", "status": "COMPLETED", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03367741", "title": "Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399448", "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03414229", "title": "A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425279", "title": "CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03435640", "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2023-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03449108", "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "status": "COMPLETED", "last_update": "2023-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463408", "title": "Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469804", "title": "Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma", "status": "UNKNOWN", "last_update": "2019-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03590210", "title": "Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03611868", "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03623581", "title": "Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)", "status": "UNKNOWN", "last_update": "2021-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628209", "title": "Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03711279", "title": "A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma", "status": "TERMINATED", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829436", "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03851614", "title": "Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03860272", "title": "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03899805", "title": "A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2025-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914612", "title": "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946943", "title": "Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma", "status": "UNKNOWN", "last_update": "2019-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04028063", "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04074564", "title": "MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2023-10-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04095208", "title": "Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04099277", "title": "A Study of LY3435151 in Participants With Solid Tumors", "status": "TERMINATED", "last_update": "2021-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04118166", "title": "Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04126993", "title": "Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma", "status": "UNKNOWN", "last_update": "2019-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165330", "title": "Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185883", "title": "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04214067", "title": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04239443", "title": "Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer", "status": "UNKNOWN", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04274023", "title": "Study on TSR-042 in Advanced Clear Cell Sarcoma", "status": "TERMINATED", "last_update": "2024-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04294511", "title": "Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma", "status": "UNKNOWN", "last_update": "2020-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04339738", "title": "Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351308", "title": "Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma", "status": "UNKNOWN", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356872", "title": "The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2020-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416568", "title": "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04420975", "title": "Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04438824", "title": "Palbociclib and INCMGA00012 in People With Advanced Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04483778", "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04535713", "title": "GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma", "status": "UNKNOWN", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04541108", "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04551430", "title": "Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579757", "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606108", "title": "Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2020-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04607200", "title": "AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma", "status": "WITHDRAWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04616248", "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624178", "title": "A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04725331", "title": "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730349", "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer", "status": "TERMINATED", "last_update": "2023-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04741438", "title": "Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype", "status": "UNKNOWN", "last_update": "2023-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04784247", "title": "Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04803877", "title": "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891718", "title": "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia", "status": "WITHDRAWN", "last_update": "2022-07-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05017103", "title": "Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study", "status": "TERMINATED", "last_update": "2024-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05026736", "title": "Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study", "status": "TERMINATED", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094804", "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents", "status": "UNKNOWN", "last_update": "2023-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05138146", "title": "A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2021-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05154630", "title": "Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors", "status": "TERMINATED", "last_update": "2024-01-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "status": "TERMINATED", "last_update": "2025-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05189483", "title": "Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.", "status": "UNKNOWN", "last_update": "2024-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193188", "title": "A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma", "status": "UNKNOWN", "last_update": "2023-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193214", "title": "A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma", "status": "UNKNOWN", "last_update": "2022-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05224999", "title": "Nivolumab for Recurrent/Metastatic Carcinosarcoma", "status": "UNKNOWN", "last_update": "2022-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238883", "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265793", "title": "Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05302921", "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05407441", "title": "Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05481645", "title": "Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy \u00b1 Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05488366", "title": "Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582031", "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers", "status": "WITHDRAWN", "last_update": "2023-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821231", "title": "Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma", "status": "COMPLETED", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05836571", "title": "Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05846724", "title": "Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma", "status": "WITHDRAWN", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05851456", "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors", "status": "UNKNOWN", "last_update": "2023-05-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05860374", "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-05-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879185", "title": "A Study of XmAb23104 in People With Sarcoma", "status": "TERMINATED", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886075", "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-06-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886634", "title": "A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941325", "title": "A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma", "status": "SUSPENDED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05961111", "title": "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084689", "title": "Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures", "status": "WITHDRAWN", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06114173", "title": "Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2023-11-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06116578", "title": "Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab", "status": "WITHDRAWN", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06128863", "title": "Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06171282", "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors", "status": "UNKNOWN", "last_update": "2023-12-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06413095", "title": "PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS", "status": "COMPLETED", "last_update": "2024-05-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494787", "title": "A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma", "status": "WITHDRAWN", "last_update": "2025-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500091", "title": "TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748872", "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06968988", "title": "Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma", "status": "SUSPENDED", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07511114", "title": "A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07576725", "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612098", "title": "Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07639242", "title": "Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC", "status": "SUSPENDED", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07695311", "title": "EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 10, "n_observational": 0, "n_active": 6, "n_withdrawn": 1, "trials": [ { "nct": "NCT04995003", "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma", "status": "RECRUITING", "last_update": "2026-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07648069", "title": "Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03282344", "title": "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356782", "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399448", "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03435640", "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2023-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04483778", "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730349", "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer", "status": "TERMINATED", "last_update": "2023-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "pembrolizumab", "nivolumab" ] }, "PDGFR-alpha": { "n": 16, "n_observational": 2, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06537596", "title": "89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00116935", "title": "Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)", "status": "COMPLETED", "last_update": "2011-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01185964", "title": "A Study of Olaratumab in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2017-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02326025", "title": "A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02377752", "title": "A Study of Olaratumab in Japanese Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02451943", "title": "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2025-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02659020", "title": "A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2022-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02783599", "title": "A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2019-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126591", "title": "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283696", "title": "A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2020-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03437070", "title": "Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma", "status": "WITHDRAWN", "last_update": "2019-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03698227", "title": "OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients", "status": "TERMINATED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784014", "title": "Molecular Profiling of Advanced Soft-tissue Sarcomas", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03985722", "title": "Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients", "status": "UNKNOWN", "last_update": "2023-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PDGFRA", "olaratumab", "Lartruvo" ] }, "TRK": { "n": 12, "n_observational": 1, "n_active": 6, "n_withdrawn": 1, "trials": [ { "nct": "NCT03093116", "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04094610", "title": "A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576431", "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650401", "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213704", "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03375437", "title": "RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.", "status": "UNKNOWN", "last_update": "2024-08-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "status": "TERMINATED", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901806", "title": "Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors", "status": "TERMINATED", "last_update": "2024-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "NTRK", "larotrectinib", "entrectinib", "repotrectinib" ] }, "B7-H3": { "n": 14, "n_observational": 3, "n_active": 11, "n_withdrawn": 0, "trials": [ { "nct": "NCT04897321", "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500819", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06778603", "title": "B7-H3 NIR Imaging for Osteosarcoma Surgery", "status": "RECRUITING", "last_update": "2025-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172958", "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222735", "title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428993", "title": "Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07751380", "title": "Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07774533", "title": "68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628535", "title": "Safety Study of MGD009 in B7-H3-expressing Tumors", "status": "TERMINATED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04433221", "title": "Combination Immunotherapy Targeting Sarcomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864821", "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06699576", "title": "ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 7, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT04897321", "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500819", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172958", "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222735", "title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428993", "title": "Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07751380", "title": "Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864821", "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "B7-H3", "CD276" ] }, "GD2": { "n": 28, "n_observational": 1, "n_active": 12, "n_withdrawn": 1, "trials": [ { "nct": "NCT03721068", "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400603", "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "status": "RECRUITING", "last_update": "2025-12-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06641908", "title": "Anti-GD2 ADC M3554 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06669013", "title": "Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas", "status": "RECRUITING", "last_update": "2024-11-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06836505", "title": "Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.", "status": "RECRUITING", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003022", "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003023", "title": "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003750", "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors", "status": "COMPLETED", "last_update": "2014-08-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445965", "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00743496", "title": "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01141491", "title": "Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free", "status": "COMPLETED", "last_update": "2017-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953900", "title": "iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107963", "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02484443", "title": "Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02502786", "title": "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03209869", "title": "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2", "status": "WITHDRAWN", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356782", "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03373097", "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03860207", "title": "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers", "status": "TERMINATED", "last_update": "2023-09-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04433221", "title": "Combination Immunotherapy Targeting Sarcomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539366", "title": "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial", "status": "SUSPENDED", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04751383", "title": "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma", "status": "TERMINATED", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05080790", "title": "Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma", "status": "COMPLETED", "last_update": "2025-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "status": "TERMINATED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438614", "title": "A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839703", "title": "International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 0, "n_active": 6, "n_withdrawn": 1, "trials": [ { "nct": "NCT03721068", "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400603", "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "status": "RECRUITING", "last_update": "2025-12-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06836505", "title": "Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.", "status": "RECRUITING", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107963", "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03209869", "title": "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2", "status": "WITHDRAWN", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356782", "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03373097", "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539366", "title": "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial", "status": "SUSPENDED", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "GD2", "dinutuximab" ] }, "MDM2": { "n": 14, "n_observational": 0, "n_active": 5, "n_withdrawn": 2, "trials": [ { "nct": "NCT04458792", "title": "Establishment of a Prospective Clinical-biological Database", "status": "RECRUITING", "last_update": "2025-02-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06578624", "title": "Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735820", "title": "Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01605526", "title": "A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343172", "title": "Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217266", "title": "Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04979442", "title": "Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma", "status": "TERMINATED", "last_update": "2025-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05012397", "title": "Milademetan in Advanced/Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180695", "title": "HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05218499", "title": "Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06058793", "title": "Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084689", "title": "Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures", "status": "WITHDRAWN", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06370871", "title": "Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma", "status": "WITHDRAWN", "last_update": "2024-07-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414434", "title": "BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "MDM2", "milademetan", "brigimadlin", "BI 907828" ] } }, "by_drug": { "ABEMACICLIB": { "n": 11, "n_observational": 0, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04040205", "title": "Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04941274", "title": "Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06025747", "title": "A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498648", "title": "Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02644460", "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02784795", "title": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846987", "title": "Study of Abemaciclib in Dedifferentiated Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05440786", "title": "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630325", "title": "A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer", "status": "TERMINATED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ALECTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "status": "TERMINATED", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ALRIZOMADLIN": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06735820", "title": "Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ALVOCIDIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00005974", "title": "Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2020-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012181", "title": "Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas", "status": "COMPLETED", "last_update": "2013-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098579", "title": "Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2013-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AVAPRITINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CATEQUENTINIB": { "n": 37, "n_observational": 1, "n_active": 17, "n_withdrawn": 1, "trials": [ { "nct": "NCT03016819", "title": "Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)", "status": "RECRUITING", "last_update": "2026-02-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05167994", "title": "Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma \uff08SPARE-01\uff09", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05926700", "title": "Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506838", "title": "Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2024-08-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153887", "title": "Vebreltinib for Advanced or Metastatic CCS", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07359053", "title": "MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma", "status": "RECRUITING", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548177", "title": "Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01878448", "title": "A Phase II Study of Anlotinib in STS Patients", "status": "COMPLETED", "last_update": "2019-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02449343", "title": "Study of Anlotinib in Patients With Soft Tissue Sarcoma\uff08STS\uff09(ALTER0203)", "status": "UNKNOWN", "last_update": "2017-04-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03416517", "title": "Anlotinib and Irinotecan for Ewing Sarcoma", "status": "UNKNOWN", "last_update": "2019-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03792542", "title": "Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy", "status": "UNKNOWN", "last_update": "2019-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03815474", "title": "Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients", "status": "UNKNOWN", "last_update": "2019-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03880695", "title": "Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2019-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890068", "title": "Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946943", "title": "Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma", "status": "UNKNOWN", "last_update": "2019-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03951571", "title": "Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2025-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165330", "title": "Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172805", "title": "Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma", "status": "COMPLETED", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04223583", "title": "Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule", "status": "COMPLETED", "last_update": "2022-03-16", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659733", "title": "Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children", "status": "UNKNOWN", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04765228", "title": "Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2021-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05121350", "title": "A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2022-02-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193188", "title": "A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma", "status": "UNKNOWN", "last_update": "2023-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05301764", "title": "A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2026-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05481645", "title": "Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy \u00b1 Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05602415", "title": "Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2022-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05656222", "title": "Irinotecan and Anlotinib for Epithelioid Sarcoma", "status": "WITHDRAWN", "last_update": "2023-02-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05844813", "title": "Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2023-05-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438783", "title": "TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors", "status": "TERMINATED", "last_update": "2025-12-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06699576", "title": "ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07156643", "title": "A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07205185", "title": "A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07355855", "title": "A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07444918", "title": "Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612098", "title": "Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07646080", "title": "Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811297", "title": "A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEDIRANIB": { "n": 8, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT00385203", "title": "The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00458731", "title": "Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma", "status": "COMPLETED", "last_update": "2014-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00942877", "title": "Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma", "status": "COMPLETED", "last_update": "2025-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01337401", "title": "A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)", "status": "UNKNOWN", "last_update": "2019-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01391962", "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma", "status": "COMPLETED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03570437", "title": "Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?", "status": "UNKNOWN", "last_update": "2022-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03660826", "title": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03851614", "title": "Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CERITINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01742286", "title": "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)", "status": "COMPLETED", "last_update": "2020-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784014", "title": "Molecular Profiling of Advanced Soft-tissue Sarcomas", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CRIZOTINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT01524926", "title": "CREATE: Cross-tumoral Phase 2 With Crizotinib", "status": "COMPLETED", "last_update": "2023-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DASATINIB": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00464620", "title": "Trial of Dasatinib in Advanced Sarcomas", "status": "COMPLETED", "last_update": "2018-11-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00788125", "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "status": "TERMINATED", "last_update": "2023-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01643278", "title": "Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic", "status": "COMPLETED", "last_update": "2017-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01916135", "title": "PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative", "status": "COMPLETED", "last_update": "2020-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03041701", "title": "Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma", "status": "TERMINATED", "last_update": "2022-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENSARTINIB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213652", "title": "Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENTRECTINIB": { "n": 6, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650401", "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03375437", "title": "RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.", "status": "UNKNOWN", "last_update": "2024-08-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "status": "TERMINATED", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FAMITINIB": { "n": 0, "n_observational": 2, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "IMATINIB": { "n": 27, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00006357", "title": "STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2012-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030667", "title": "Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031915", "title": "Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062205", "title": "Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor", "status": "COMPLETED", "last_update": "2010-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075400", "title": "Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer", "status": "COMPLETED", "last_update": "2019-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00084630", "title": "Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085475", "title": "Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma", "status": "COMPLETED", "last_update": "2012-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00090987", "title": "Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00116935", "title": "Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)", "status": "COMPLETED", "last_update": "2011-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00117299", "title": "PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib", "status": "COMPLETED", "last_update": "2010-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00122473", "title": "Imatinib in Dermatofibrosarcoma Protuberans (DFSP)", "status": "COMPLETED", "last_update": "2011-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00154388", "title": "Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases", "status": "COMPLETED", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00171912", "title": "Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes", "status": "COMPLETED", "last_update": "2017-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00243191", "title": "Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans", "status": "COMPLETED", "last_update": "2012-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00278876", "title": "Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation", "status": "COMPLETED", "last_update": "2020-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00359333", "title": "Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST", "status": "COMPLETED", "last_update": "2013-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00367861", "title": "Prospective Multicentric Randomized Study of Glivec\u00ae in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance", "status": "COMPLETED", "last_update": "2014-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00385203", "title": "The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400569", "title": "Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2012-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00427583", "title": "Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors", "status": "TERMINATED", "last_update": "2012-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00767819", "title": "Treatment of Patients With RAD001 With Progressive Sarcoma", "status": "COMPLETED", "last_update": "2019-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01046487", "title": "Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate", "status": "COMPLETED", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01275222", "title": "Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors", "status": "COMPLETED", "last_update": "2021-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01281865", "title": "Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2014-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01524848", "title": "Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib", "status": "COMPLETED", "last_update": "2017-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02413736", "title": "Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04138381", "title": "Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)", "status": "UNKNOWN", "last_update": "2023-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IMETELSTAT": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01273090", "title": "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma", "status": "COMPLETED", "last_update": "2014-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011126", "title": "Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "status": "WITHDRAWN", "last_update": "2018-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAROTRECTINIB": { "n": 4, "n_observational": 1, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT02576431", "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213704", "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MOTESANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01273090", "title": "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma", "status": "COMPLETED", "last_update": "2014-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011126", "title": "Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "status": "WITHDRAWN", "last_update": "2018-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03217266", "title": "Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NINTEDANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02808247", "title": "Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma", "status": "TERMINATED", "last_update": "2021-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NINTEDANIB ESYLATE": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02808247", "title": "Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma", "status": "TERMINATED", "last_update": "2021-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OLARATUMAB": { "n": 13, "n_observational": 1, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT06537596", "title": "89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01185964", "title": "A Study of Olaratumab in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2017-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02326025", "title": "A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02377752", "title": "A Study of Olaratumab in Japanese Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02451943", "title": "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2025-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02659020", "title": "A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2022-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02783599", "title": "A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2019-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126591", "title": "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283696", "title": "A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2020-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03437070", "title": "Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma", "status": "WITHDRAWN", "last_update": "2019-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03698227", "title": "OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients", "status": "TERMINATED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03985722", "title": "Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients", "status": "UNKNOWN", "last_update": "2023-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PALBOCICLIB": { "n": 16, "n_observational": 0, "n_active": 8, "n_withdrawn": 2, "trials": [ { "nct": "NCT04025541", "title": "Analysis of Circulating Tumor Markers in Blood", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06113809", "title": "Palbociclib and Pembrolizumab in Sarcoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06843967", "title": "A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01209598", "title": "PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma", "status": "COMPLETED", "last_update": "2017-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02897375", "title": "Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03242382", "title": "Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.", "status": "UNKNOWN", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526250", "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709680", "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784014", "title": "Molecular Profiling of Advanced Soft-tissue Sarcomas", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04129151", "title": "Palbociclib + Ganitumab In Ewing Sarcoma", "status": "TERMINATED", "last_update": "2024-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185883", "title": "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04438824", "title": "Palbociclib and INCMGA00012 in People With Advanced Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655598", "title": "TAS-116 Plus Palbociclib in Breast and Rb-null Cancer", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694871", "title": "Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PAZOPANIB": { "n": 55, "n_observational": 2, "n_active": 8, "n_withdrawn": 3, "trials": [ { "nct": "NCT04199026", "title": "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05679921", "title": "Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma", "status": "RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239272", "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06263231", "title": "A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06816771", "title": "Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents", "status": "RECRUITING", "last_update": "2025-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07444619", "title": "A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00297258", "title": "Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2016-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00722293", "title": "A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00753688", "title": "Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy", "status": "COMPLETED", "last_update": "2013-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00929903", "title": "Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01012362", "title": "Study of Pazopanib and Ixabepilone in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01059656", "title": "Phase II Pazopanib Study in Advanced Dermatofibrosarcomas", "status": "TERMINATED", "last_update": "2016-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130623", "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01247571", "title": "Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer", "status": "COMPLETED", "last_update": "2019-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01330966", "title": "Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01392352", "title": "HYPAZ: Hypertension Induced by Pazopanib", "status": "TERMINATED", "last_update": "2020-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01418001", "title": "Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)", "status": "TERMINATED", "last_update": "2018-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01438554", "title": "Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma", "status": "COMPLETED", "last_update": "2018-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01442662", "title": "Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine", "status": "COMPLETED", "last_update": "2020-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01446809", "title": "Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2020-04-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01462630", "title": "Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma", "status": "COMPLETED", "last_update": "2022-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01468922", "title": "Pazopanib and ARQ 197 for Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01506596", "title": "Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01524848", "title": "Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib", "status": "COMPLETED", "last_update": "2017-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01532687", "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2021-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01543763", "title": "Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01543802", "title": "Study of Preoperative Therapy With Pazopanib (Votrient\u00ae) to Treat High-risk Soft Tissue Sarcoma", "status": "TERMINATED", "last_update": "2021-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01593748", "title": "A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01692496", "title": "Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial", "status": "COMPLETED", "last_update": "2020-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01719302", "title": "Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2016-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01759303", "title": "Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung", "status": "TERMINATED", "last_update": "2021-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861951", "title": "A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2017-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01956669", "title": "Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975519", "title": "A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2020-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01985295", "title": "Combined Modality Treatment of Sarcomas of the Extremities", "status": "COMPLETED", "last_update": "2015-10-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049905", "title": "Phase 3 Study to Treat Patients With Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2024-06-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02113826", "title": "Pazopanib for Metastatic Alveolar Soft Part Sarcoma", "status": "TERMINATED", "last_update": "2017-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02180867", "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02203760", "title": "Pazopanib Vs. Pazopanib Plus Gemcitabine", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02207309", "title": "Pazopanib Maintenance Phase II", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02212015", "title": "Evaluation of Votrient in Angiosarcoma", "status": "TERMINATED", "last_update": "2022-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02300545", "title": "Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy", "status": "COMPLETED", "last_update": "2020-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02357810", "title": "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas", "status": "COMPLETED", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02367651", "title": "Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma", "status": "WITHDRAWN", "last_update": "2016-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02575066", "title": "Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients", "status": "TERMINATED", "last_update": "2019-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02601209", "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma", "status": "TERMINATED", "last_update": "2022-08-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02795819", "title": "Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer", "status": "TERMINATED", "last_update": "2019-10-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02979899", "title": "Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma", "status": "COMPLETED", "last_update": "2020-05-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03139331", "title": "PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma", "status": "COMPLETED", "last_update": "2021-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03149120", "title": "Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas", "status": "WITHDRAWN", "last_update": "2017-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03660930", "title": "Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas", "status": "TERMINATED", "last_update": "2025-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735758", "title": "Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib", "status": "TERMINATED", "last_update": "2021-09-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03798106", "title": "A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2023-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04741438", "title": "Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype", "status": "UNKNOWN", "last_update": "2023-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180695", "title": "HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "QUIZARTINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02668653", "title": "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "REGORAFENIB": { "n": 18, "n_observational": 0, "n_active": 7, "n_withdrawn": 1, "trials": [ { "nct": "NCT04055220", "title": "Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas", "status": "RECRUITING", "last_update": "2026-02-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625907", "title": "FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma", "status": "RECRUITING", "last_update": "2024-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04698785", "title": "Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients", "status": "RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01900743", "title": "Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02048371", "title": "SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes", "status": "COMPLETED", "last_update": "2023-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02048722", "title": "Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma", "status": "COMPLETED", "last_update": "2022-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02085148", "title": "A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02307500", "title": "Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy", "status": "COMPLETED", "last_update": "2022-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02389244", "title": "A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas", "status": "COMPLETED", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03793361", "title": "Phase II Study of Regorafenib as Maintenance Therapy", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04803877", "title": "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198934", "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395741", "title": "Regorafenib in Patients With Refractory Primary Bone Tumors", "status": "COMPLETED", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582031", "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers", "status": "WITHDRAWN", "last_update": "2023-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05830084", "title": "Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041490", "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation", "status": "NOT_YET_RECRUITING", "last_update": "2023-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06820957", "title": "Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "REPOTRECTINIB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03093116", "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04094610", "title": "A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "RIBOCICLIB": { "n": 8, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT04025541", "title": "Analysis of Circulating Tumor Markers in Blood", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343172", "title": "Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02571829", "title": "A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma", "status": "UNKNOWN", "last_update": "2016-11-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03009201", "title": "Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2023-08-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03096912", "title": "A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma", "status": "UNKNOWN", "last_update": "2017-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03114527", "title": "Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429502", "title": "Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "RIPRETINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02571036", "title": "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2023-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SIREMADLIN": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02343172", "title": "Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180695", "title": "HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SORAFENIB": { "n": 24, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT07787429", "title": "Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00217620", "title": "S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2014-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238121", "title": "Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer", "status": "COMPLETED", "last_update": "2015-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00245102", "title": "Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma", "status": "COMPLETED", "last_update": "2014-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00287495", "title": "BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma", "status": "TERMINATED", "last_update": "2019-12-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00330421", "title": "Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)", "status": "COMPLETED", "last_update": "2014-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00406601", "title": "BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2010-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00541840", "title": "Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma", "status": "UNKNOWN", "last_update": "2008-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00703638", "title": "Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2017-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00822848", "title": "Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2018-09-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00837148", "title": "Sorafenib and Dacarbazine in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2015-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00864032", "title": "Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall", "status": "COMPLETED", "last_update": "2013-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00874874", "title": "Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery", "status": "UNKNOWN", "last_update": "2009-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00880542", "title": "Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery", "status": "TERMINATED", "last_update": "2020-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00889057", "title": "Sorafenib in Relapsed High Grade Osteosarcoma", "status": "COMPLETED", "last_update": "2013-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01005797", "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers", "status": "COMPLETED", "last_update": "2017-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01371981", "title": "Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01518413", "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2015-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01804374", "title": "Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma", "status": "COMPLETED", "last_update": "2015-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01871766", "title": "Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01946529", "title": "Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors", "status": "COMPLETED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02050919", "title": "Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2022-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02711007", "title": "Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy", "status": "COMPLETED", "last_update": "2018-04-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041490", "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation", "status": "NOT_YET_RECRUITING", "last_update": "2023-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB": { "n": 17, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT03900793", "title": "Losartan + Sunitinib in Treatment of Osteosarcoma", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07477457", "title": "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma", "status": "RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00378911", "title": "Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus", "status": "COMPLETED", "last_update": "2019-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400569", "title": "Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2012-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00474994", "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas", "status": "COMPLETED", "last_update": "2016-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521092", "title": "Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma", "status": "WITHDRAWN", "last_update": "2014-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00753727", "title": "Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma", "status": "UNKNOWN", "last_update": "2011-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00767819", "title": "Treatment of Patients With RAD001 With Progressive Sarcoma", "status": "COMPLETED", "last_update": "2019-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00859456", "title": "Sunitinib in Certain Subtypes of Soft Tissue Sarcomas", "status": "TERMINATED", "last_update": "2019-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01061411", "title": "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2022-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01164228", "title": "Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01391962", "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma", "status": "COMPLETED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01498835", "title": "Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2017-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01524848", "title": "Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib", "status": "COMPLETED", "last_update": "2017-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277924", "title": "Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03641326", "title": "Sunitinib in Sarcomas of the Central Nervous System", "status": "TERMINATED", "last_update": "2022-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06208748", "title": "SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB MALATE": { "n": 17, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT03900793", "title": "Losartan + Sunitinib in Treatment of Osteosarcoma", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07477457", "title": "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma", "status": "RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00378911", "title": "Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus", "status": "COMPLETED", "last_update": "2019-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400569", "title": "Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2012-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00474994", "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas", "status": "COMPLETED", "last_update": "2016-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521092", "title": "Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma", "status": "WITHDRAWN", "last_update": "2014-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00753727", "title": "Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma", "status": "UNKNOWN", "last_update": "2011-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00767819", "title": "Treatment of Patients With RAD001 With Progressive Sarcoma", "status": "COMPLETED", "last_update": "2019-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00859456", "title": "Sunitinib in Certain Subtypes of Soft Tissue Sarcomas", "status": "TERMINATED", "last_update": "2019-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01061411", "title": "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2022-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01164228", "title": "Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01391962", "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma", "status": "COMPLETED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01498835", "title": "Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma", "status": "COMPLETED", "last_update": "2017-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01524848", "title": "Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib", "status": "COMPLETED", "last_update": "2017-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277924", "title": "Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03641326", "title": "Sunitinib in Sarcomas of the Central Nervous System", "status": "TERMINATED", "last_update": "2022-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06208748", "title": "SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TIVOZANIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05000294", "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01782313", "title": "A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas", "status": "COMPLETED", "last_update": "2019-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRILACICLIB": { "n": 4, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06699472", "title": "A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib", "status": "RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06714383", "title": "Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma", "status": "RECRUITING", "last_update": "2024-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217003", "title": "Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma", "status": "UNKNOWN", "last_update": "2024-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "UCN-01": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VATALANIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00117299", "title": "PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib", "status": "COMPLETED", "last_update": "2010-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00348790", "title": "Vatalanib in Treating Patients With Recurrent or Progressive Meningioma", "status": "COMPLETED", "last_update": "2018-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02711007", "title": "Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy", "status": "COMPLETED", "last_update": "2018-04-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] } } } }